$-13.87
(Market cap
$29,945 Mln
Recently Viewed
Clear AllMarket cap
$29,945 Mln
Revenue (TTM)
$16,310 Mln
P/E Ratio
21.9
P/B Ratio
4.4
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$1,360 Mln
ROE
0.2 %
ROCE
6.3 %
Industry P/E
--
EV/EBITDA
12.3
Debt to Equity
2.5
Book Value
$37.8
EPS
$7.9
Face value
--
Shares outstanding
167,866,339
CFO
$14,718.45 Mln
EBITDA
$19,632.32 Mln
Net Profit
$6,311.59 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
IQVIA Holdings (IQV)
| -28.4 | -2.8 | -32.5 | 12.3 | -7.3 | -6.5 | 8.7 |
|
BSE Sensex
| -8.3 | 4.2 | -5.6 | -2.4 | 9.2 | 10.1 | 11.6 |
|
S&P 100
| 1.3 | 10.1 | 2.5 | 37.6 | 22.9 | 13.3 | 14.2 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
IQVIA Holdings (IQV)
| 14.7 | -15.0 | 12.9 | -27.4 | 57.5 | 16.0 | 33.0 |
|
S&P 100
| 18.7 | 29.0 | 30.8 | -22.1 | 27.6 | 19.3 | 29.5 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
IQVIA Holdings (IQV)
|
161.3 | 29,945.3 | 16,310.0 | 1,360.0 | 14.2 | 21.6 | 21.9 | 4.4 |
| 312.6 | 41,317.3 | 3,713.9 | 313.8 | 11.2 | 73.3 | 133.5 | 52.4 | |
| 143.1 | 31,186.3 | 606.4 | -1,276.8 | -196.7 | -249.3 | -- | 42.2 | |
| 74.6 | 12,506.7 | 944.0 | -381.0 | -31.6 | -70.7 | -- | 25.6 | |
| 54.7 | 21,304.7 | 1,944.0 | -2,822.0 | -142.4 | -28.9 | -- | 2.5 | |
| 131.4 | 13,402.6 | 2,860.5 | 478.6 | 24.1 | 16.4 | 28.5 | 4.1 | |
| 754.6 | 79,350.1 | 14,342.9 | 4,504.9 | 36.8 | 14.9 | 18.1 | 2.5 | |
| 23.3 | 19,500.6 | 0.0 | -1,079.6 | -- | -206.1 | -- | 29.6 | |
| 571.8 | 25,787.3 | 3,182.7 | 1,334.7 | 54.1 | 19.7 | 21.1 | 3.6 | |
| 437.8 | 112,223.5 | 12,074.6 | 3,953.2 | 38.4 | 22.5 | 28.8 | 5.9 |
IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments:... Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and associated implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. is based in Durham, North Carolina. Read more
CEO & Chairman
Mr. Ari Bousbib
CEO & Chairman
Mr. Ari Bousbib
Headquarters
Durham, NC
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of IQVIA Holdings Inc (IQV) is $161.34 (NYSE) as of 23-Apr-2026 10:44 EDT. IQVIA Holdings Inc (IQV) has given a return of -7.27% in the last 3 years.
The P/E ratio of IQVIA Holdings Inc (IQV) is 21.92 times as on 17-Apr-2026.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
28.49
|
5.96
|
|
2024
|
25.88
|
5.86
|
|
2023
|
31.40
|
6.98
|
|
2022
|
35.42
|
6.70
|
|
2021
|
56.90
|
9.10
|
The 52-week high and low of IQVIA Holdings Inc (IQV) are Rs 247.05 and Rs 134.65 as of 23-Apr-2026.
IQVIA Holdings Inc (IQV) has a market capitalisation of $ 29,945 Mln as on 17-Apr-2026. As per SEBI classification, it is a Large Cap company.
Before investing in IQVIA Holdings Inc (IQV), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.